Efficacy and Safety of Turmeric in Prevention of Lupus Flare in Chloroquine or Hydroxychloroquine Withdrawing Patients
Efficacy and Safety of Turmeric in Prevention of Lupus Flare
Keywords:
turmeric, prevention of lupus flare, chloroquine or hydroxychloroquine withdrawing patientsAbstract
Systemic lupus erythematosus is an perspective autoimmune, multisystemic inflammatory disease.
Chloroquine or hydroxychloroquine and anti-inflammatory drugs are used for treatment. When disease
is remission, anti-inflammatory drugs are stop, only the chloroquine or hydroxychloroquine is used to
prevent lupus flare. Retinopathy is related to the cumulative dose of both drugs leading to drug withdrawing
in some of lupus patients. Turmeric has anti-inflammatory effects similar to hydroxychloroquine, but there
is no used for lupus flare. This study conducted a double-blind randomized control study to assess
the efficacy and safety of turmeric compare with placebo in prevention of lupus flare in Buddhachinaraj
Phitsanulok Hospital. Twenty-nine, stable disease for at least 3 months and both drugs withdrawing patients
were randomized into two groups with patients receiving turmeric (750 mg/d) and placebo for 52 weeks.
The primary endpoint was changing in SLEDAI every 12 weeks. The secondary endpoint was defined:
severe exacerbation, increased or doubling prednisolone dosage > 0.5 mg/kg/day, adding immunosuppressive
drugs and admission due to severe disease flare. Patients in turmeric group showed statistically
significant lower SLEDAI, 1.8-fold prevented mild to moderate disease flare, 1.6-fold prevented severe
disease flare. Patients in turmeric group had two times greater chance of suviving from crisis than a placebo
group (24/12 weeks). Turmeric treatment did not related with any adverse events. This study provides
the efficacy and safety of turmeric in prevention of lupus flare in chloroquine or hydroxychloroquine
withdrawing patients, and highlights the need for future large-scale trials to validate these findings.
References
2. Gensous N, Marti A, Barnetche T, Blanco P, Lazaro E, Seneschal J, et al. Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review. Arthritis Res Ther 2017;19(1):1442-6.
3. Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 1991;34(8):937-44.
4. Kakati S, Teronpi R, Barman B. Frequency, pattern, and determinants of flare in systemic lupus erythematosus: A study from North East India. Egypt Rheumatol 2015;37(4):S55-9.
5. Mirzayan MJ, Schmidt RE, Witte T. Prognostic parameters for flare in systemiclupus erythematosus. Rheumatology 2000;39(12):1316-9.
6. Nikpour M, Urowitz MB, Iba ez D, Gladman DD. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 2009;61(9):1152-8.
7. Silva JC, Mariz HA, Rocha LF Jr, Oliveira PS, Dantas AT, Duarte AL, et al. Hydroxychloroquine decreases Th17 -related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics (Sao Paulo) 2013;68(6):766-71.
8. Willis R, Seif AM, McWin G Jr, Martinez-Martinez LA, Gonzalez EB, Dang N, et al. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activityin SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus 2012;21(8):830-5.
9. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991;324(3):150-4.
10. Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cividino A, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998;7(2):80-5.
11. Meinao IM, Sato EI, Andrade LE, Ferraz MB, Atra E. Controlled trial with chloroquinediphosphate in systemic lupus erythematosus. Lupus 1996;5(Suppl 1):s41-s44.
12. Ruiz-Irastorza G, Egurbide MV, PijoanJ I, Garmendia M, Villar J, Martinez-Berriotxoa A, et al. Effects of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006;15(9):577-83.
13. Pons-Estel GJ, Alarcon GS, McGwin G. Jr, Danila MI, Zhang J, Bastian HM, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: data from LUMINA, a multiethnic U.S. cohort. Arthritis Rheum 2009;61(6):830-9.
14. Parikh SV, Rovin BH. Current and Emerging Therapies for Lupus Nephritis. J Am Soc Nephrol 2016;27(10):2929-39.
15. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF. American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011;118(2):415-22.
16. Meiler WF. New monitoring guidelines for hydroxychloroquine. Presented at Retina Subspecialty Day, 2010 Oct 10, Chicago.
17. Ruther K, Foerster J, Berndt S, Schroeter J. Chloroquine/hydroxychloroquine: variability of retinotoxic cumulative doses. Ophthalmology 2007;104(10):875-9.
18. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010;69(1):20-8.
19. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003;23(1A):363-98.
20. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 2009;14(2):141-53.
21. Momtazi-Borojeni AA, Haftcheshmeh SM, Esmaeili SA, Johnston TP, Abdollahi E, Sahebkar A. Curcumin: A natural modulator of immune cells in systemic lupus erythematosus. Autoimmun Rev 2018;17(2):125-35.
22. Lee H, Kim H, Lee G, Chung HS, Bae H. Curcumin attenuates lupus nephritis upon interaction with regulatory T cells in New Zealand Black/White mice. Br J Nutr 2013;110(1):69-76.
23. Khajehdehi P, Zanjaninejad B, Aflaki E, Nazarinia M, Azad F, Malekmakan L, et al. Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study. J Ren Nutr 2012;22(1):50-7.
24. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25(11):1271-7.
25. Lam GKW, Petri M. Assessment of systemic lupus erythematosus. Clin Exp Rheumatol 2005;23(5 Suppl 39):S120-32.
26. Ngamjarusn C, Chongsuvivatwon V, Mc Nei E. 4 Studies: sample size calculation for an epidemiological study on a smart device. Siriraj Med J 2016;68(3):160-70.
